Title |
Chinese herbal medicine Huangqi type formulations for nephrotic syndrome
|
---|---|
Published in |
Cochrane database of systematic reviews, June 2013
|
DOI | 10.1002/14651858.cd006335.pub3 |
Pubmed ID | |
Authors |
Mei Feng, Wei Yuan, Renzhong Zhang, Ping Fu, Taixiang Wu |
Abstract |
Patients with primary nephrotic syndrome mostly need immunosuppression to achieve remission, but many of them either relapse after immunosuppression therapy or resistant to it. On the other hand, immunosuppression therapy could increase the adverse effect. Huangqi and Huangqi type formulations have been used to treat nephrotic syndrome for years in China, however the effects and safety of these formulations have not been systematically reviewed. This is an update of a review first published in 2008. |
X Demographics
The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
Country | Count | As % |
---|---|---|
Australia | 1 | 50% |
Unknown | 1 | 50% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 2 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 127 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
Country | Count | As % |
---|---|---|
United Kingdom | 1 | <1% |
Ireland | 1 | <1% |
Unknown | 125 | 98% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Master | 17 | 13% |
Researcher | 13 | 10% |
Student > Ph. D. Student | 12 | 9% |
Student > Bachelor | 10 | 8% |
Other | 9 | 7% |
Other | 21 | 17% |
Unknown | 45 | 35% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 40 | 31% |
Nursing and Health Professions | 12 | 9% |
Biochemistry, Genetics and Molecular Biology | 6 | 5% |
Psychology | 4 | 3% |
Pharmacology, Toxicology and Pharmaceutical Science | 3 | 2% |
Other | 13 | 10% |
Unknown | 49 | 39% |
Attention Score in Context
This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 17 June 2022.
All research outputs
#14,657,487
of 25,457,858 outputs
Outputs from Cochrane database of systematic reviews
#9,845
of 11,842 outputs
Outputs of similar age
#110,732
of 210,184 outputs
Outputs of similar age from Cochrane database of systematic reviews
#232
of 285 outputs
Altmetric has tracked 25,457,858 research outputs across all sources so far. This one is in the 41st percentile – i.e., 41% of other outputs scored the same or lower than it.
So far Altmetric has tracked 11,842 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 38.9. This one is in the 13th percentile – i.e., 13% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 210,184 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 46th percentile – i.e., 46% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 285 others from the same source and published within six weeks on either side of this one. This one is in the 18th percentile – i.e., 18% of its contemporaries scored the same or lower than it.